| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/02/2013 | US8475817 Dry personal cleansing article comprising a surface with water insoluble non-fibrous projections of ethylene-vinyl acetate copolymer; and releasable lathering surfactant; mechanically agitating and/or deforming article; hair and skin conditioners; single use, disposable products |
| 07/02/2013 | US8475815 Alloplastic injectable dermal filler and methods of use thereof |
| 07/02/2013 | US8475814 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 07/02/2013 | US8475813 Methods of treatment using a gastric retained gabapentin dosage |
| 07/02/2013 | US8475804 Compositions and methods for treatment of filovirus-mediated diseases |
| 07/02/2013 | US8475782 Cytotoxic properties or cell adhesion properties by grafting; exposure copolymer to liquid solution contasining microbiocides, fungicides, viricides |
| 07/02/2013 | US8475781 Cyclodextrin-based polymers for therapeutics delivery |
| 07/02/2013 | US8475780 Ion binding polymers and uses thereof |
| 07/02/2013 | US8475779 Methods of treating disease with random copolymers |
| 07/02/2013 | US8475776 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| 07/02/2013 | US8475770 Foamable suspension gel |
| 07/02/2013 | CA2750209C Coated solid preparations of valproic acid |
| 07/02/2013 | CA2748249C Cyclic amine compounds |
| 07/02/2013 | CA2742946C Antioxidant |
| 07/02/2013 | CA2737694C Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| 07/02/2013 | CA2731897C Diazepine and diazocane compounds as mc4 agonists |
| 07/02/2013 | CA2716918C Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| 07/02/2013 | CA2687608C Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| 07/02/2013 | CA2684599C Crystalline forms of topotecan hydrochloride and processes for making the same |
| 07/02/2013 | CA2657469C Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 07/02/2013 | CA2650033C Compositions and methods useful for treatment of respiratory illness |
| 07/02/2013 | CA2647893C Pharmaceutical composition comprising lipase inhibitor and lipophilic oil absorbent and oral formulation prepared therefrom |
| 07/02/2013 | CA2637573C 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives |
| 07/02/2013 | CA2619219C Use of .beta.-1,3 (4)-endoglucanohydrolase, .beta.-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 07/02/2013 | CA2601360C Sclerostin and the inhibition of wnt signaling and bone formation |
| 07/02/2013 | CA2599879C Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient |
| 07/02/2013 | CA2590223C Oral compositions containing extracts of rosmarinus and related methods |
| 07/02/2013 | CA2589928C Process for the preparation of drospirenone |
| 07/02/2013 | CA2588293C Rasagiline orally disintegrating compositions |
| 07/02/2013 | CA2584684C Reverse micelle composition for delivery of metal cations comprising a diglyceride and a phytosterol and method of preparation |
| 07/02/2013 | CA2579844C Topical endoparasiticide and ectoparasiticide formulations |
| 07/02/2013 | CA2578368C Triazolophthalazines |
| 07/02/2013 | CA2576839C N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 07/02/2013 | CA2575933C Stabilised prostaglandin composition |
| 07/02/2013 | CA2575821C Dihydropteridinone infusion solution having a long shelf life |
| 07/02/2013 | CA2573338C A nutritional composition comprising dried fruit solids and an oligosaccharide and its use for treating osteoporosis |
| 07/02/2013 | CA2563760C Pharmaceutical compositions comprising glycopyrrolate |
| 07/02/2013 | CA2562904C Cancer treatment using viruses and camptothecins |
| 07/02/2013 | CA2560559C Aqueous intraocular penetration-promoting eye drop |
| 07/02/2013 | CA2553721C Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination |
| 07/02/2013 | CA2545112C Novel ligands that are activators of the rar receptors, use in human medicine and in cosmetics |
| 07/02/2013 | CA2540536C Salts and polymorphs of a potent antidiabetic compound |
| 07/02/2013 | CA2539766C Benzimidazole derivates: preparation and pharmaceutical applications |
| 07/02/2013 | CA2535483C Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 07/02/2013 | CA2533117C Combinations for the treatment of depression |
| 07/02/2013 | CA2530736C Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
| 07/02/2013 | CA2521379C Pharmaceutical formulations containing methylnaltrexone |
| 07/02/2013 | CA2519705C Antifungal nail coat and method of use |
| 07/02/2013 | CA2509419C Macrolides |
| 07/02/2013 | CA2504582C Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer |
| 07/02/2013 | CA2502025C Pharmaceutical compositions having a modified vehicle |
| 07/02/2013 | CA2485597C Process for preparation of cyclic prodrugs of pmea and pmpa |
| 07/02/2013 | CA2476041C Delta 6-desaturases from primulaceae, expressing plants and pufa-containing oils |
| 07/02/2013 | CA2470964C Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 07/02/2013 | CA2462871C In vitro model for priocidal activity |
| 07/02/2013 | CA2421151C Modified vaccinia ankara virus variant |
| 07/02/2013 | CA2373178C The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| 07/02/2013 | CA2277778C Specific pancreatic lipase inhibitors and their applications |
| 07/02/2013 | CA2251009C Medicament for optimising mucosal viscosity and stimulating intestinal function |
| 06/30/2013 | CA2800329A1 Methods and compositions for treating diabetes |
| 06/28/2013 | CA2799624A1 Dialysis and substitution fluid |
| 06/27/2013 | WO2013096926A1 E-selectin antagonist compounds, compositions, and methods of use |
| 06/27/2013 | WO2013096907A1 Methods and compositions for combination therapy using p13k/mtor inhibitors |
| 06/27/2013 | WO2013096878A1 Garcinia buchananii baker compounds, compositions and related methods |
| 06/27/2013 | WO2013096870A1 Compositions and methods for treating amyotrophic lateral sclerosis |
| 06/27/2013 | WO2013096836A1 Photolabile compounds |
| 06/27/2013 | WO2013096820A1 Anti-cancer compounds targeting ral gtpases and methods of using the same |
| 06/27/2013 | WO2013096788A1 Process for manufacturing partially cross-linked alginate solution |
| 06/27/2013 | WO2013096785A1 2-substituted-thienoquinolones and related compounds as anti-infective agents |
| 06/27/2013 | WO2013096744A1 Hepatitis b antiviral agents |
| 06/27/2013 | WO2013096735A1 Novel therapeutic agents |
| 06/27/2013 | WO2013096709A2 Methods of increasing the viability or longevity of an organ or organ explant |
| 06/27/2013 | WO2013096689A1 Anti allergen composition and spray formulation comprising the same |
| 06/27/2013 | WO2013096687A1 Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| 06/27/2013 | WO2013096684A1 Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
| 06/27/2013 | WO2013096681A1 Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| 06/27/2013 | WO2013096680A1 Substituted phosphorothioate nucleotide analogs |
| 06/27/2013 | WO2013096679A1 Substituted nucleosides, nucleotides and analogs thereof |
| 06/27/2013 | WO2013096642A1 Heteroaryls and uses thereof |
| 06/27/2013 | WO2013096637A1 Heteroaryls and uses thereof |
| 06/27/2013 | WO2013096630A1 Heteroaryls and uses thereof |
| 06/27/2013 | WO2013096577A1 Antimicrobial composition for animal welfare |
| 06/27/2013 | WO2013096512A1 Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders |
| 06/27/2013 | WO2013096501A1 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 06/27/2013 | WO2013096496A2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 06/27/2013 | WO2013096448A1 Composition, preparation, and use of dense chitosan membrane materials |
| 06/27/2013 | WO2013096444A1 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
| 06/27/2013 | WO2013096430A1 Method of treating cancer with magea3 immunotherapeutic with braf inhibitor and/or mek inhibitor |
| 06/27/2013 | WO2013096423A1 Combination therapy with interferon and andrographolides for multiple sclerosis |
| 06/27/2013 | WO2013096405A1 Chewing gum products containing [(2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester |
| 06/27/2013 | WO2013096226A1 Trpv1 antagonists |
| 06/27/2013 | WO2013096194A1 Novel heterocyclic carboxamides as modulators of kinase activity |
| 06/27/2013 | WO2013096182A2 Compositions comprising gallates and gallamides |
| 06/27/2013 | WO2013096176A1 Hemostatic materials and devices with galvanic particulates |
| 06/27/2013 | WO2013096173A1 Contact lenses containing carotenoid and method for making same |
| 06/27/2013 | WO2013096150A1 Substituted piperidines as hdm2 inhibitors |
| 06/27/2013 | WO2013096093A1 Compounds as dgat-1 inhibitors |
| 06/27/2013 | WO2013096060A1 Compounds for inhibiting the interaction of bcl2 with binding partners |
| 06/27/2013 | WO2013096059A1 Compounds for inhibiting the interaction of bcl2 with binding partners |
| 06/27/2013 | WO2013096055A1 Compounds for inhibiting the interaction of bcl2 with binding partners |